Wave Life Sciences Ltd (NASDAQ:WVE) Receives Average Recommendation of “Buy” from Analysts

Share on StockTwits

Wave Life Sciences Ltd (NASDAQ:WVE) has received an average recommendation of “Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $45.00.

A number of equities analysts have commented on the company. ValuEngine raised Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 29th. Guggenheim began coverage on Wave Life Sciences in a research note on Friday, November 1st. They issued a “buy” rating and a $43.00 price objective for the company. BidaskClub raised Wave Life Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Mizuho started coverage on shares of Wave Life Sciences in a report on Thursday, November 21st. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th.

In other news, Director Gregory L. Verdine sold 30,039 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.63, for a total transaction of $920,094.57. Following the transaction, the director now owns 36,009 shares of the company’s stock, valued at approximately $1,102,955.67. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 39.70% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bailard Inc. lifted its stake in shares of Wave Life Sciences by 97.6% in the 2nd quarter. Bailard Inc. now owns 83,000 shares of the company’s stock valued at $2,165,000 after purchasing an additional 41,000 shares during the last quarter. Aperio Group LLC acquired a new position in Wave Life Sciences during the second quarter worth $51,000. Janus Henderson Group PLC lifted its stake in Wave Life Sciences by 16.1% during the second quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock worth $88,505,000 after purchasing an additional 470,402 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Wave Life Sciences during the second quarter worth $604,000. Finally, Swiss National Bank boosted its position in shares of Wave Life Sciences by 2.4% during the second quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $892,000 after buying an additional 800 shares during the period. Institutional investors and hedge funds own 90.00% of the company’s stock.

Shares of WVE stock traded down $0.13 on Tuesday, reaching $34.10. 365,843 shares of the company were exchanged, compared to its average volume of 328,216. Wave Life Sciences has a 1 year low of $17.59 and a 1 year high of $50.98. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.88 and a current ratio of 1.88. The business has a 50-day moving average price of $26.70 and a 200 day moving average price of $24.12. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -6.77 and a beta of 0.91.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.34) by ($0.14). Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. The firm had revenue of $2.93 million during the quarter, compared to analyst estimates of $6.30 million. As a group, equities analysts anticipate that Wave Life Sciences will post -5.54 earnings per share for the current year.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Story: Why do company’s buyback their stock?

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.